Literature DB >> 2655718

Effect of the 5-HT2 antagonist ketanserin on the ECT-induced prolactin release.

A P Zis1, H K Manji, R A Remick, B E Grant, C M Clark.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2655718     DOI： 10.1016/0006-3223(89)90012-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  3 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Ritanserin, a 5-HT2 receptor antagonist, does not modify ECT-induced prolactin release.

Authors:  Y Papakostas; M Markianos; G Papadimitriou; C Stefanis
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans.

Authors:  M A Lee; J F Nash; M Barnes; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.